PET/CT can be indispensable as a diagnostic and prognostic tool; in the assessment of patient response to therapy and cancer recurrence; even in the choice of therapy. And the significance of this hybrid imaging modality could grow in future years.
Digitalization is increasing the medical value of PET/CT, according to Brian Gordon, M.D., who interprets the majority of digital PET/CTs performed at the WellStar Kennestone Cancer Center in Marietta, Ga.
“An improved patient experience is the major advantage of digital PET/CT,” said Gordon, head of Nuclear Medicine for Quantum Radiology, a subspecialty radiology group that interprets images for the sprawling WellStar Health System.
The digital detector built into the Vereos PET/CT from Philips Healthcare improves sensitivity and, consequently, the detectability of small lesions. And it does so while reducing scan time.
The result is an enhanced patient experience, according to Gordon. The Vereos replaced an analog PET/CT at the WellStar Kennestone Cancer Center in November 2017. Since then, PET/CT scan volume has reached as high as 18 patients per day.
Despite the high throughput, which ranges from this peak to about a dozen scans per day, scan accuracy is excellent, he said. The WellStar Kennestone Cancer Center is one of the busiest PET/CT providers in the state of Georgia, he said.
The digital detector has dropped scan times for whole body exams from 50 to 30 minutes and ones from the base of the skull to mid-thigh from 30 to 20 minutes.
The vast majority of scans at the center are oncologic. Many are ordered to evaluate suspicious lesions that were spotted initially on CTs or MRIs, but Vereos is also used extensively to monitor patient response to cancer therapy and to look for cancer recurrence.
Although shorter scan times have boosted throughput at the cancer center and improved the patient experience, accuracy is the top priority, Gordon said. The increased sensitivity of the digital detector improves image quality, while short scan times make the patient more comfortable and less prone to move.
This reduces the likelihood of motion artifacts that can degrade images. The short scans do not reduce image quality, Gordon emphasized. On the contrary, compared with analog PET/CT that operated before Vereos, he said, “we can detect activity in smaller lesions.”
The ability to detect very small lesions is critically important when PET/CT is applied in staging or monitoring. This is where the digital detector excels, according to Philips’ Director of Clinical Science for Nuclear Medicine Piotr Maniawski.
“Digital technology allows us to improve small lesion detectability,” said Maniawski who has worked in nuclear medicine for more than three decades, mostly at Philips Healthcare. Digital PET/CT is well suited to find recurrent disease and characterize the patient response to therapy while providing the option of fast scans, he said.